<DOC>
	<DOC>NCT01769716</DOC>
	<brief_summary>This open-label study aims to evaluate the safety and efficacy of autologous or allogeneic umbilical cord blood therapy for children with global developmental delay.</brief_summary>
	<brief_title>Umbilical Cord Blood Therapy for Global Developmental Delay</brief_title>
	<detailed_description>Global developmental delay is defined as significant delay in two or more of the following developmental domains: gross/fine motor, speech/language, cognition, social/personal, and activities of daily living. Umbilical cord blood has been used for inherited metabolic diseases that feature global developmental delay and many experimental animal studies have revealed umbilical cord blood is useful to repair neurological impairments in brain.</detailed_description>
	<criteria>Global developmental delay Willing to comply with all study procedure Medical instability including pneumonia or renal function at enrollment Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for followup Uncontrolled persistent epilepsy Not eligible according to the principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Global developmental delay</keyword>
	<keyword>Umbilical cord blood</keyword>
	<keyword>Rehabilitation</keyword>
</DOC>